Department of Radiology, Division of Nuclear Medicine and Molecular imaging, 70 Francis Street, Shapiro 5th Floor, Room 128, Boston, MA 02115, USA.
Curr Cardiol Rep. 2013 May;15(5):352. doi: 10.1007/s11886-013-0352-8.
Cardiac involvement portends a poor prognosis in patients with sarcoidosis. However, due to the nonspecific clinical manifestations of the disease, patchy myocardial involvement, and the limited diagnostic yield of diagnostic tests, early diagnosis of cardiac sarcoidosis has been exceedingly difficult. As a result, there is no standardized approach for the early diagnosis of cardiac sarcoidosis. Imaging modalities that can both identify disease and predict response to therapy are paramount to improve management of cardiac sarcoidosis. (18)F-FDG PET has many practical advantages in assessing disease activity and monitoring treatment response in patients with cardiac sarcoidosis. Accumulating data support the growing role of (18)F-fluorodeoxyglucose ((18)F-FDG) PET in the diagnosis and risk stratification of patients with cardiac sarcoidosis.
心脏受累预示着肉样瘤病患者预后不良。然而，由于该病临床表现无特异性、心肌受累呈斑片状以及诊断性检查的检出率有限，心脏肉样瘤病的早期诊断极其困难。因此，目前还没有心脏肉样瘤病的早期诊断标准化方法。能够识别疾病并预测治疗反应的成像方式对于改善心脏肉样瘤病的管理至关重要。(18)F-氟脱氧葡萄糖（(18)F-FDG）PET 在评估心脏肉样瘤病患者的疾病活动度和监测治疗反应方面具有许多实际优势。越来越多的数据支持(18)F-氟脱氧葡萄糖（(18)F-FDG）PET 在心脏肉样瘤病患者的诊断和危险分层中的作用。
